Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (402)	9/30/1998 2:35:00 PM
From: Marty	Read Replies (1) \| Respond to of 857

First, thanks for sharing your DD. I can't understand how Asensio, et. al. can get away with their statements. As I understand it, using the internet to misrepresent or distort the truth is considered wire fraud, a federal offense. Also that passing on false info about a publicly held company violates SEC regulations. There must be something that they rely on to cover them from both liability and jail time. I know now that posters can't rely on their anonymity to save them as SI, AOL, and YHOO can be forced to supply the names and aliases of the posters. Maybe they don't know that or think that plain faulty research isn't a crime. I think that HEB can prove that Asensio and the ones who have been trying to drive the price down to profit on their short positions went way beyond just poor research.

To: RealMuLan who wrote (402)	9/30/1998 10:12:00 PM
From: RealMuLan	Read Replies (1) \| Respond to of 857

Wednesday September 30, 6:54 pm Eastern Time Clarification: CFIDS Sufferers Estimated at 500,000 in U.S., 2 Million Worldwide Chronic Fatigue Sufferers Over 4 Million in U.S. Alone Company Press Release SOURCE: Hemispherx Biopharma NEW YORK, Sept. 30 /PRNewswire/ -- Hemispherx Biopharma (Amex: HEB - news) today said that the findings of the Annals of Internal Medicine article cited in a release issued by the company earlier today support previous statements that the incidence of Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) is about half a million people in the U.S. and 2 million worldwide, with millions more suffering from Chronic Fatigue alone. The July 15, 1995 Annals of Medicine article (p. 81) states that the estimated crude point prevalence of CFIDS ''... ranged from 76 to 267 cases per 100,000 persons.'' Given the U.S. Census Bureau estimate of the current U.S. population of 270.7 million (available at www.census.gov), this incidence rate translates to a range of 205,732 to 722,769. The Annals of Medicine article (p. 81) further stated that ''... the prevalence of chronic fatigue alone was strikingly higher; it ranged from 1,776 to 6,321 cases per 100,000 persons.'' This incidence rate translates to a range of 4-6 million people. These figures are consistent with the CFIDS estimates that Hemispherx has been disseminating to investors, as reflected in its shareholder publications and in the recent research reports that have been published by the analysts who follow the company closely. Hemispherx's recent general letter to shareholders dated July 20, 1998 stated that CFIDS ''... affects over 500,000 persons in the United States and over 2 million persons worldwide,'' which is the wording intended for today's earlier release. The June 25, 1998 analyst report by Value Management and Research stated that CFIDS ''... affects approximately 600,000 people in the U.S. and another 600,000 in Europe.'' The July 21, 1998 report by Biovest stated that CFIDS affects an ''... estimated 500,000 patients in the U.S.'' Similar estimates have appeared in numerous Hemispherx press releases. The only analyst report that has been seriously in error was one issued on September 22, 1998 by Asensio & Company, which estimated the U.S. incidence of CFIDS at about 26,000. The Asensio & Company estimate, which is about 20 times lower than the consensus estimates, apparently relied on outdated estimates made by the Centers for Disease Control in the early 1990s, which the CDC itself repudiated several years ago. SOURCE: Hemispherx Biopharma